Venture Point Business Park
58 Evans Road
+44 151 728 4500
ChargePoint technology are market leaders in the manufacturing of sterile and high containment split butterfly valves for use pharmaceutical and bio-pharmaceutical ingredient processing.
ChargePoint Technology originally developed the patented split butterfly valve technology developed in conjunction with Glaxo Pharmaceuticals (now GlaxoSmithKline) in 1996. Known as a CTC, 'Contained Transfer Coupling', the fundamental features of the valve are still retained in the design as it can be seen today.
The patented split butterfly valve technology has become a pharmaceutical industry standard for the contained transfer of potent compounds from process to process.
ChargePoint’s product range includes:
#Congratulations đźŽ‰ One of our #NPHExportChamps đźŹ† @ChargePointTech have been named in the London Stock Exchange Group's 1000 Companies to Inspire Britain report for 2018 đź‡¬đź‡§đź’Ľ— Dept. Int. Trade NW (@tradegovuk_NW) May 17, 2018
See the full list â¤µď¸Źhttps://t.co/qrmGJOOYb3 pic.twitter.com/3RyM806yTw
ChargePoint are pleased to announce we have been included in the London Stock Exchange Group's 1000 Companies to Inspire Britain report for 2018! Read more about the report here: https://t.co/qai1c4WYzP— ChargePointTech (@ChargePointTech) May 16, 2018